Cytosorbents (CTSO) Stock: Buy, Sell, or Hold?
CTSO - Cytosorbents Corp.
$6.41
0.04 (0.63%)
▲
5d:
+1731.43%
30d:
+1632.43%
90d:
+1551.64%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CTSO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CTSO is 85.8% above its trading range ($3.45). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CTSO is 85.8% above its trading range ($3.45). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CTSO is currently trading at $6.41, which is considered extended relative to its 30-day fair value range of $-0.91 to $3.45.
Technical Outlook: Technically, CTSO is showing sideways momentum. Immediate support is located at $0.31, while resistance sits at $7.44.
Market Sentiment: CTSO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.50 (+641.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTSO is showing sideways momentum. Immediate support is located at $0.31, while resistance sits at $7.44.
Market Sentiment: CTSO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.50 (+641.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.91 -
$3.45
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+85.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 641.0% below Wall St target ($47.50)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.91 -
$3.45
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.31
Resistance Level
$7.44
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.20
Wall Street Target
$47.50
(+641.0%)
Revenue Growth (YoY)
0.2%
Profit Margin
-48.9%
Share & Embed Analysis
Last updated: September 13, 2026 10:41 AM ET
Data refreshes hourly during market hours. Next update: 11:41 AM
Data refreshes hourly during market hours. Next update: 11:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTSO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$62 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$376 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
